Contact information
Department of Translational Genomics
TRIO Research Center
University of Cologne
Robert-Koch-Straße 21
50931 Cologne
CV
Academic education
2004 - 2009 | PhD, Physics - Complex Systems, Sharif University of Technology, Tehran |
2003 - 2004 | MSc, Physics - Transferred to PhD, Sharif University of Technology, Tehran |
1999 - 2003 | BSc, Physics - Iran University of Science and Technology, Tehran |
Scientific degrees
11/2009 | PhD, Physics - Complex Systems, Sharif University of Technology, Tehran (Supervisors: Prof. M. R. Rahimitabar) |
Scientific career
2016 - present | Postdoctoral Fellow, Computational Cancer Genomics, University of Cologne |
2011 - 2016 | Postdoctoral Fellow, Mathematical Modeling of Biological Systems, Heinrich Heine University, Düsseldorf |
2009 - 2011 | Postdoctoral Fellow, Institute for Research in Fundamental Sciences (IPM), Tehran |
Honors/ Awards/ Memberships
2012 - 2014 | EMBO Long-Term Fellowship, 2011, European Molecular Biology Organization |
2003 | Ranked 32th amongst nearly 6000 participants in the University Entrance Exam for M.Sc degree in Physics |
2003 | 1st Rank amongst 45 Department Alumni in B.Sc. |
1998 | Silver Medalist of the 11th National Physics Olympiad |
Relevant industry experience
2012 | Recommendation System Development using Deep Machine Learning Technologies as a collaboration project from industry in Prof. Kollmann’s Lab, Heinrich Heine University, Düsseldorf |
Publications
-
CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature
The identification of the mutational processes operating in tumour cells has implications for cancer diagnosis and therapy. These processes leave mutational patterns on the cancer genomes, which are referred to as mutational signatures. Recently, 81 mutational signatures have been inferred using…
-
Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Pleomorphic dermal sarcoma (PDS) is a rare malignant cutaneous tumor with an unknown cell of origin. Locally defined tumors can be treated by curative excisions, whereas advanced stages of the disease are difficult to treat, using standard regimens. We performed whole-exome sequencing on a cohort…
-
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels
Tumour heterogeneity encompasses both the malignant cells and their microenvironment. While heterogeneity between individual patients is known to affect the efficacy of cancer therapy, most personalized treatment approaches do not account for intratumour heterogeneity. We addressed this issue by…
-
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Genomic profiling revealed the identity of at least 5 subtypes of diffuse large B-cell lymphoma (DLBCL), including the MCD/C5 cluster characterized by aberrations in MYD88, BCL2, PRDM1, and/or SPIB. We generated mouse models harboring B cell–specific Prdm1 or Spib aberrations on the background of…